At a glance
- Originator Mitsubishi Pharma Corporation; Tohoku University
- Class Antidementias; Antidepressants; Antiepileptic drugs; Antihistamines; Neuroprotectants
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 22 May 1995 Discontinued-Preclinical for Epilepsy in Japan (Unknown route)